Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$34.36 From HK$30.59, Keeps at Buy

MT Newswires03:44 ET · Ratings

Announcement Highlights | Kuaishou's adjusted Net income in Q4 increased by 7.8% year-on-year, and the total revenue of Keliang AI exceeded 0.1 billion yuan; CHINA TELECOM will earn 33 billion yuan in net income in 2024.

CHINA TELECOM's net income in 2024 is 33 billion yuan; WULING MOTORS' net income attributable to shareholders is expected to increase by over 115% in 2024; Kuaishou's net income in 2024 is 15.335 billion yuan, an increase of 139.76% year-on-year.

cls.cn20:37 ET

Hong Kong Stock Morning Report | US stock index closed higher while Chinese concept stocks fell, Morgan Stanley raised the target point for the Hang Seng Index.

① The results of the Saudi talks between the USA, Russia, and Ukraine have been disclosed, achieving a consensus on a ceasefire in the Black Sea. ② Consumer confidence in the USA further deteriorated in March. ③ The three main US stock indices rose on Tuesday, while China Concept Stocks declined. ④ Data shows that the US stock market is in a state of "Institutions fleeing, retail investors buying heavily." ⑤ According to sources, Trump is considering implementing a two-step tariff system on April 2. ⑥ Morgan Stanley has raised the year-end target point for the Hang Seng Index.

cls.cn19:06 ET

WUXI BIO's net income decline narrowed to 1.3%, with North America accounting for more than half of the revenue | Interpretations

In 2024, revenue is projected to be 18.675 billion yuan, an increase of 9.6% year-on-year, with a net income of 3.356 billion yuan, a decrease of 1.3% compared to last year. Revenue from North America reached 10.696 billion yuan, growing by 32.48% compared to 2023, accounting for 57.3% of total revenue.

cls.cnMar 25 11:44 ET

WUXI BIO (02269) annual report observation: "Low valuation + high growth", Global CXO leader's valuation urgently needs strong repair.

Today, WUXI BIO (02269) announced its annual report, indicating that the company achieved revenue of 18.68 billion yuan in 2024, with non-COVID revenue growing by 13.1% year-on-year; gross profit increased by 12.1% to 7.65 billion yuan; and EBITDA rose by 16.7% to 6.55 billion yuan. From 2014 to 2024, the company's non-COVID revenue compound annual growth rate is about 50%.

Zhitong FinanceMar 25 07:53 ET

WuXi Biologics' Profit Slides 1.3% in 2024

MT NewswiresMar 25 06:55 ET